Читать книгу Practical Cardiovascular Medicine - Elias B. Hanna - Страница 76

1 87. Fox KA, Mehta SR, Peters R. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial. Circulation 2004; 110: 1202–18.

2 88. Mauri L, Kereiakes DJ, Yeh RW, et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–66.

3 89. Yeh RW, Secemsky E, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary intervention: an analysis from the randomized Dual Antiplatelet Therapy Study. JAMA 2016; 315(16):1735–1749.

4 90. Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 2016; 68(17): 1851-1864. In this meta-analysis, patients with complex anatomy are still better served with 12 months of DAPT

5 91. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–1988.

6 92. Levin GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guidelines focused update on duration of antiplatelet therapy in patients with coronary artery disease. J Am coll Cardiol 2016; 68 (10): 1082–1115.

7 93. Naidu SS, Krucoff MW, Rutledge DR, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after Xience V implantation. JACC Cardiovasc Interv 2012; 5: 626–35.

8 94. Colombo A, Chieffo A, Frasheri A, et al. Second generation drug-eluting stent implantation followed by 6- versus 12- month dual antiplatelet therapy. J Am Coll Cardiol 2014; 64: 2086–97. SECURITY trial, stable CAD. Similar results were seen in the OPTIMIZE trial (3- versus 12-month of dual antiplatelet therapy).

9 95. Palmerini T, Biondi-Zoccai G, Della Riva D. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–402. Everolimus-eluting stent is associated with an even lower risk of stent thrombosis than BMS and any other DES.

10 96. Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 2015; 65: 1092–102.

11 97. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125: 2015–26. PRODIGY trial, 56% MI.